Pagoclone
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Pagoclone is an
It binds with roughly equivalent high affinity (0.7–9.1 nM) to the benzodiazepine
The pharmacologist David Nutt has suggested pagoclone as a possible base from which to make a better social drug, as it produces the positive effects of alcohol, such as relaxation and sociability, but without also causing the negative effects like aggression, amnesia, nausea, loss of coordination and liver damage. Its effect can be quickly reversed by the action of flumazenil, which is already used as an antidote to benzodiazepine overdose.[5] Nutt has published studies[6] praising the potential of pagoclone which were financed by Indevus which was seeking funding for a possible production of the compound. The long-term safety of pagoclone has not been assessed. The abuse potential of pagoclone has been assessed as being similar to, or slightly less than that of diazepam and it would also be expected to be somewhat safer due to its relatively weaker sedative effects,[7] but development of pagoclone as a commercial drug would still be unlikely due to concerns about abuse.[citation needed]
Pagoclone was trialed as a drug to improve a
Synthesis
Pagoclone and pazinaclone both contain an isoindolone structural motif
Reaction of 2-Amino-7-chloro-1,8-